Swiftmerge Acquisition Corp. (IVCP)

HDL Therapeutics to Go Public in Merger with Swiftmerge Acquisition Corp.

NEW YORK & VERO BEACH, Fla., August 11, 2023--HDL Therapeutics, Inc. ("HDL Therapeutics"), a privately held commercial stage biotech company with an FDA-approved cardiovascular therapy the Plasma Delipidation System (PDS-2™ System) for reducing coronary atheroma in patients with homozygous familial hypercholesterolemia (HoFH), has signed a definitive merger agreement with Swiftmerge Acquisition Corp. (NASDAQ: IVCP) ("Swiftmerge"), a special purpose acquisition company with a disruptive consumer